Ken Griffin Verve Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 7,500 shares of VERV stock, worth $47,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,500

Previous 12,400 39.52%

Holding current value

$47,250

Previous $60,000 40.0%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.4 - $7.86 $1.05 Million - $1.87 Million	237,695 Added 46.85%	745,055 $3.61 Million
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $3.19 Million - $8.57 Million	-669,725 Reduced 56.9%	507,360 $2.48 Million
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $7.86 Million - $13.1 Million	727,265 Added 161.68%	1,177,085 $15.6 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $1.88 Million - $3.98 Million	212,617 Added 89.64%	449,820 $6.27 Million
Q3 2023 Nov 14, 2023	SELL	$11.42 - $20.82 $5.24 Million - $9.55 Million	-458,837 Reduced 65.92%	237,203 $3.15 Million
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $3.62 Million - $5.4 Million	271,178 Added 63.83%	696,040 $13.1 Million
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $5.55 Million - $9.32 Million	388,028 Added 1053.45%	424,862 $6.13 Million
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $606,828 - $1.38 Million	-33,996 Reduced 48.0%	36,834 $712,000
Q3 2022 Nov 14, 2022	SELL	$15.63 - $41.49 $15.8 Million - $41.9 Million	-1,010,725 Reduced 93.45%	70,830 $2.43 Million

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $378M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account